Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities.
Title | Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Fountzilas, E., Levva S., Mountzios G., Polychronidou G., Maniadakis N., Kotoula V., & Fountzilas G. |
Journal | J Glob Oncol |
Volume | 4 |
Pagination | 1-12 |
Date Published | 2018 09 |
ISSN | 2378-9506 |
Keywords | Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Economic Recession, ErbB Receptors, Greece, Humans, Medical Oncology, Mutation, Protein Kinase Inhibitors |
Abstract | PURPOSE: Because of the profound financial crisis that commenced in Greece in 2010, severe cuts in health care spending and other restriction measures led to significant delays in the reimbursement of novel antineoplastic agents. In 2011, the Hellenic Society of Medical Oncology initiated a program of early access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of patients with advanced, EGFR-mutant non-small-cell lung cancer (NSCLC). We evaluated treatment patterns and clinical outcomes in patients with EGFR-mutant or wild-type disease treated at a large center in Greece throughout the period of financial crisis. |
DOI | 10.1200/JGO.18.00115 |
Alternate Journal | J Glob Oncol |
PubMed ID | 30260753 |
PubMed Central ID | PMC6223495 |